Condition: High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements · Recurrent Diffuse Large B-Cell Lymphoma · Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type · Sponsor: National Cancer Institute (NCI)
This phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse large B-cell lymphoma (DLBCL) and high-grade lymphoma with MYC and BCL2 rearrangements that has come back after a period of improvement (relapsed) and/or that has not responded to previous treatment (refractory). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Ibrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers at abnormal levels. This may help keep cancer cells from growing and spreading. Anti-inflammatory drugs, such as prednisone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Obinutuzumab, a monoclonal antibody, binds to a protein called CD20, which is found on B cells and some types of leukemia and lymphoma cells. Obinutuzumab may block CD20 and help the immune system kill cancer cells. Revlimid, a type of anti-angiogenesis agent and a type of immunomodulating agent, may help the immune system kill abnormal blood cells or cancer cells. It may also prevent the growth of new blood vessels that cancers need to grow. ViPOR may be an effective treatment option for patients with relapsed and/or refractory CD10 negative D…
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Banner University Medical Center - Tucson | Tucson, Arizona, United States | Suspended |
| University of Arizona Cancer Center-North Campus | Tucson, Arizona, United States | Suspended |
| Cedars-Sinai Medical Center | Los Angeles, California, United States | Recruiting |
| Smilow Cancer Hospital-Derby Care Center | Derby, Connecticut, United States | Recruiting |
| Smilow Cancer Hospital Care Center - Guilford | Guilford, Connecticut, United States | Recruiting |
| Yale University | New Haven, Connecticut, United States | Recruiting |
| Kootenai Health - Coeur d'Alene | Coeur d'Alene, Idaho, United States | Suspended |
| Kootenai Clinic Cancer Services - Post Falls | Post Falls, Idaho, United States | Suspended |
| Kootenai Clinic Cancer Services - Sandpoint | Sandpoint, Idaho, United States | Suspended |
| Northwestern University | Chicago, Illinois, United States | Recruiting |
| Carle at The Riverfront | Danville, Illinois, United States | Suspended |
| Northwestern Medicine Cancer Center Kishwaukee | DeKalb, Illinois, United States | Recruiting |
+ 74 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06649812